GSK & Sanofi join forces to discover an effective vaccine for COVID-19
Category: #health  | By Nikita Chaurasia  | Date: 2020-04-15 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

GSK & Sanofi join forces to discover an effective vaccine for COVID-19

Amidst growing concerns over the coronavirus, numerous medical institutes and pharmaceutical companies are diligently working on developing an effective vaccine to tackle this deadly virus. France’s Sanofi S.A. and Britain’s GlaxoSmithKline plc (GSK) are a shining example of this statement as two of the world’s largest vaccine creators join forces to develop and mass produce a vaccine for COVID-19.

Reportedly, the pharma giants are planning to commence vaccine trials by the second half of 2020 and, if everything goes as per the plan, will make them widely accessible by Q2 of 2021.

According to Paul Hudson, Chief Executive Officer, Sanofi, during these unprecedented times where the whole world is going through a health crisis, a single company wouldn’t be able to tackle this issue. As a result, Sanofi believes it is beneficial for it to share its resources and expertise with its partners and allies like GSK. The main focus of this partnership is to create and provide ample quantities of drugs that would help cure this disease.

Currently, the market is crowded with dozens of teams ranging from universities to firms such as Moderna, Inovio and Johnson & Johnson who are constantly working on drug development and clinical trials. Most of them are on the verge of developing a sure shot vaccine for COVID-19, with almost 78 candidates being actively tested.

However, Sanofi and GSK believe that their size would give them a decisive edge over competitors, as the infected patients figure scales up to almost 2 million worldwide.

Speaking on the development, David Loew, Executive Vice President of Vaccine Branch, Sanofi Pasteur, said that the real challenge is to not just discover a suitable vaccine candidate but also to produce it at a massive scale, scaling up to hundreds of millions of doses.

Source Credit: https://www.euronews.com/2020/04/14/coronavirus-vaccine-pharma-giants-gsk-and-sanofi-team-up-to-find-covid-19-solution

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Shell trades off Russian retail business to native oil producer Lukoil

Shell trades off Russian retail business to native oil producer Lukoil

By Nikita Chaurasia

Energy giant Shell plans on selling more than 400 petrol stations of its Russian subsidiary Shell Neft to Lukoil, the second largest oil producer in the country after state backed Rosneft. As several Western oil and gas firms seek to get rid of th...

Mitsubishi, Siemens sign an MoU to cooperate in SiC traction technology

Mitsubishi, Siemens sign an MoU to cooperate in SiC traction technology

By Nikita Chaurasia

Mitsubishi Electric Europe and Siemens Mobility have recently signed a memorandum of understanding (MoU) to work together in silicon carbide (SiC) traction power technology. As per reports, JR Central’s next-generation N700S Shinkansen train...

Legato opens 80 new jobs in its Limerick Research & Development hub

Legato opens 80 new jobs in its Limerick Research & Development hub

By Nikita Chaurasia

The global capability center of a leading U.S. health care insurance company, Legato Health Technologies is planning to build an additional 80 posts at its Limerick facility. It would bring the total number of staff to 200, which the fir...